Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 – 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study

Moshe Talpaz, Josef T. Prchal, Lawrence B. Afrin, Murat O. Arcasoy, Solomon I. Hamburg, Jason Clark, Deanna Kornacki, Philomena Colucci, Srđan Verstovšek

2021Clinical Lymphoma Myeloma & Leukemia17 citationsDOI Open Access PDF

Topics & Concepts

RuxolitinibMedicineMyelofibrosisOpen labelOpen label studyInternal medicinePhases of clinical researchPlateletOncologyGastroenterologyClinical trialAdverse effectBone marrowMyeloproliferative Neoplasms: Diagnosis and TreatmentPlatelet Disorders and TreatmentsMultiple Myeloma Research and Treatments

Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 – 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study

Topics & Concepts

Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 – 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study